David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Veeco
VECO
$2.91B
| $12.2M | 0.02% |
1,129,006
+100,895
| +10% | +$1.04M |
|
952
nVent Electric
NVT
$24.5B
| $12.2M | 0.02% |
453,516
-40,505
| -8% | -$1.04M |
|
953
Molson Coors Class B
TAP
$7.83B
| $12.2M | 0.02% |
205,035
-967,424
| -83% | -$59.7M |
|
954
CALL
HCA Healthcare
HCA
$92.8B
| $12.2M | 0.02% |
93,500
-9,300
| -9% | -$1.25M |
|
955
Corning
GLW
$127B
| $12.2M | 0.02% |
+367,874
| New | +$12.1M |
|
956
Urban Outfitters
URBN
$6.49B
| $12.2M | 0.02% |
410,127
+281,254
| +218% | +$8.66M |
|
957
PUT
Charter Communications
CHTR
$18.5B
| $12.1M | 0.02% |
35,000
-20,100
| -36% | -$6.62M |
|
|
WFT
958
DELISTED
Weatherford International plc
WFT
| $12.1M | 0.02% |
17,378,078
+9,780,697
| +129% | +$6.77M |
|
959
MacroGenics
MGNX
$266M
| $12.1M | 0.02% |
673,243
+652,694
| +3,176% | +$11.3M |
|
|
RARX
960
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $12.1M | 0.02% |
538,846
+291,604
| +118% | +$6.27M |
|
961
Dr. Reddy's Laboratories
RDY
$10.3B
| $12.1M | 0.02% |
1,489,290
-89,365
| -6% | -$679K |
|
962
World Kinect Corp
WKC
$1.81B
| $12M | 0.02% |
416,875
-314,873
| -43% | -$8.27M |
|
|
CVSA
963
Covista Inc
CVSA
$4.64B
| $12M | 0.02% |
259,883
-139,524
| -35% | -$6.71M |
|
964
Raymond James Financial
RJF
$33.6B
| $12M | 0.02% |
223,982
+185,397
| +480% | +$9.93M |
|
965
ACI Worldwide
ACIW
$5.29B
| $12M | 0.02% |
364,119
+94,804
| +35% | +$2.89M |
|
966
Iridium Communications
IRDM
$4.99B
| $12M | 0.02% |
452,456
-139,616
| -24% | -$3M |
|
|
VRTSP
967
DELISTED
Virtus Investment Partners, Inc. 7.25% Series D Mandatory Convertible Preferred Stock
VRTSP
| $11.9M | 0.02% |
134,645
+20,970
| +18% | +$1.8M |
|
968
GSK
GSK
$104B
| $11.9M | 0.02% |
227,741
-201,939
| -47% | -$10.1M |
|
|
GHDX
969
DELISTED
Genomic Health, Inc.
GHDX
| $11.9M | 0.02% |
169,828
-75,712
| -31% | -$5.61M |
|
970
Imperial Oil
IMO
$63.6B
| $11.9M | 0.02% |
435,169
-876,758
| -67% | -$23.9M |
|
|
TMHC
971
DELISTED
Taylor Morrison
TMHC
| $11.9M | 0.02% |
669,517
-581,148
| -46% | -$10.4M |
|
972
ATI
ATI
$29.3B
| $11.9M | 0.02% |
463,554
-361,007
| -44% | -$9.51M |
|
973
Digital Realty Trust
DLR
$71.2B
| $11.8M | 0.02% |
99,366
+9,472
| +11% | +$1.06M |
|
974
CALL
General Mills
GIS
$21.3B
| $11.8M | 0.02% |
228,400
+49,800
| +28% | +$2.26M |
|
975
CALL
RTX Corp
RTX
$283B
| $11.8M | 0.02% |
145,076
+73,571
| +103% | +$5.59M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.